Loading
A phase 2 trial of retifanlimab in pancreatic cancer, run by Massachusetts General Hospital, not yet recruiting.
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC is a phase 2, interventional study registered as NCT07765836 by Massachusetts General Hospital, with a registry enrolment figure of 40 participants, started 2027-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: vilastobart (XTX101); Retifanlimab. Conditions listed: Pancreatic Cancer Metastatic. Primary outcome: Objective response rate (ORR). Pancreatic eligibility wording from the registry: "* Participant must have histologically proven metastatic pancreatic cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.